IDH mutations have been described in patients with other hematologic malignancies such as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs), highlighting the broad importance of IDH in the pathogenesis of myeloid malignancies [10]. This evidence concerns the gene IDH1 and myeloproliferative disorder.